No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CABA Cabaletta Bio
- 12.190
- -0.690-5.36%
Close May 21 16:00 ET
- 12.650
- +0.460+3.77%
Post 19:08 ET
588.49MMarket Cap-7128P/E (TTM)
13.140High11.980Low1.14MVolume12.780Open12.880Pre Close13.94MTurnover2.62%Turnover RatioLossP/E (Static)48.28MShares26.35052wk High2.65P/B529.60MFloat Cap9.02052wk Low--Dividend TTM43.45MShs Float26.350Historical High--Div YieldTTM9.01%Amplitude0.590Historical Low12.260Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $30 Price Target
Cabaletta Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 136.41% HC Wainwright & Co. → $30 Reiterates Buy → Buy 04/05/2024 294.01% Cantor Fitzgerald → $
Express News | Cabaletta Bio Inc : Jefferies Cuts Target Price to $31 From $36
Cabaletta Bio's Promising Clinical Advancements and Stable Financial Outlook Merit a Buy Rating
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) fell sharply during Wednesday's session after the company reported first-quarter financial results.Bolt Biotherapeutics posted a GAAP loss of 28 cent
William Blair Reaffirms Their Buy Rating on Cabaletta Bio (CABA)
Comments
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
23
$Cabaletta Bio(CABA.US$ isn't it great that we now punish good stocks with good news... they need to fix this crap, all these meidcal companies rely a lot on share prices...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
diamonds : 请问，ENDPQ重组后，持有的股票还能有效吗？